{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:12:04Z","timestamp":1779297124942,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>One of the greatest success stories of modern medicine is the prevention of infectious diseases by vaccination, most notably against smallpox and poliomyelitis. However, recent events, such as the 2009\u20132010 swine flu and the 2020 COVID-19 pandemics, as well as the continued emergence of highly pathogenic avian influenza viruses highlighted the fact that we still need to develop new vaccines, and perhaps we should be proactive, rather than reacting to epidemics and pandemics. However, the development of tools for evaluating novel vaccines has not been able to keep up with the rate of vaccine production. Humoral and cellular immune responses to vaccination have both been suggested to be important in preventing infections or ameliorating their consequences, although there is uncertainty regarding their exact roles and importance. This, together with the rapid development of new vaccines, means that the need for developing immunogenicity parameters, and even more importantly, reliable correlates of protection, is more important than ever.<\/jats:p>","DOI":"10.3390\/v16111671","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T07:51:29Z","timestamp":1729842689000},"page":"1671","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Developing Correlates of Protection for Vaccines Is Needed More than Ever\u2014Influenza, COVID-19 and RSV Infection"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-1694","authenticated-orcid":false,"given":"Zoltan","family":"Vajo","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Semmelweis University Medical School, 1085 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6493-824X","authenticated-orcid":false,"given":"Csaba","family":"Laszlofy","sequence":"additional","affiliation":[{"name":"Department of Prosthodontics, Faculty of Dentistry, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2020.08.019","article-title":"History of the plague: An ancient pandemic for the age of COVID-19","volume":"134","author":"Glatter","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_2","first-page":"21","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proceedings (Bayl. Univ. Med. Cent.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.32607\/20758251-2017-9-4-4-12","article-title":"40 Years without Smallpox","volume":"9","author":"Shchelkunova","year":"2017","journal-title":"Acta Nat."},{"key":"ref_4","unstructured":"(2024, March 14). Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/CVI.00327-08","article-title":"Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains","volume":"16","author":"Fazekas","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.medj.2021.08.004","article-title":"Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens","volume":"2","author":"Mysore","year":"2021","journal-title":"Med"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1750-2659.2008.00055.x","article-title":"Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval\u2014A useful approach to pandemic vaccine development even in less well developed countries?","volume":"2","author":"Vajo","year":"2008","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_8","unstructured":"(2024, August 11). Vaccines Licensed for Use in the United States, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states."},{"key":"ref_9","unstructured":"European Committee for Proprietary Medicinal Products (2024, March 14). Note for Guidance on Harmonization of Requirements for Influenza Vaccines, 12 March 1997 (CPMP\/BWP\/214\/96). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-harmonisation-requirements-influenza-vaccines_en.pdf."},{"key":"ref_10","unstructured":"(2024, August 14). Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines, F.D.A, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-data-needed-support-licensure-seasonal-inactivated-influenza-vaccines."},{"key":"ref_11","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J. Hyg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1532-5415.1994.tb01746.x","article-title":"Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak","volume":"42","author":"Gravenstein","year":"1994","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_14","first-page":"63","article-title":"Haemagglutination-inhibiting antibody to influenza virus","volume":"115","author":"Palache","year":"2003","journal-title":"Dev. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Laszlofy, C., Fazekas, G., Barath, Z., and Vajo, Z. (2024). Evaluation of Vaccine Immunogenicity\u2014Correlates to Real-World Protection: Influenza. Viruses, 16.","DOI":"10.3390\/v16030441"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Domnich, A., Manini, I., Panatto, D., Calabr\u00f2, G.E., and Montomoli, E. (2020). Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials. Vaccines, 8.","DOI":"10.3390\/vaccines8020325"},{"key":"ref_17","first-page":"E1","article-title":"Impact of erythrocyte species on assays for influenza serology","volume":"59","author":"Trombetta","year":"2018","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_18","unstructured":"(2024, October 01). U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research MAY 2007. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines, Available online: https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Guidance-for-Industry--Clinical-Data-Needed-to-Support-the-Licensure-of-Pandemic-Influenza-Vaccines.pdf."},{"key":"ref_19","unstructured":"(2024, October 01). Guidance on Development and Implementation of a National Deployment and Vaccination Plan for Vaccines Against Pandemic Influenza and Other Respiratory Viruses of Pandemic Potential. ISBN 978-92-4-008487-2. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240084872."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/14760584.3.6.643","article-title":"Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine","volume":"3","author":"Belshe","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41577-020-0338-x","article-title":"The non-specific and sex-differential effects of vaccines","volume":"20","author":"Aaby","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/595861","article-title":"Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004\u20132005 season to the 2006\u20132007 season","volume":"199","author":"Belongia","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-med-120617-041310","article-title":"Is a Universal Influenza Virus Vaccine Possible?","volume":"71","author":"Nachbagauer","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11255-021-03076-2","article-title":"Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients","volume":"54","author":"Tillmann","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Miller, E. (2022). Predicting the efficacy of new coronavirus vaccines\u2014Are neutralising antibodies enough?. EBioMedicine, 79.","DOI":"10.1016\/j.ebiom.2022.104034"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhang, S., Xu, K., Li, C., Zhou, L., Kong, X., Peng, J., Zhu, F., Bao, C., Jin, H., and Gao, Q. (2022). Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.829665"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"a007252","DOI":"10.1101\/cshperspect.a007252","article-title":"Vaccine design for CD8 T lymphocyte responses","volume":"1","author":"Koup","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiac327","article-title":"Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1\/2 Randomized Clinical Trial","volume":"227","author":"Davis","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults","volume":"388","author":"Papi","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1671\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:20:27Z","timestamp":1760113227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["v16111671"],"URL":"https:\/\/doi.org\/10.3390\/v16111671","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}